Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound and method for regulating plasminogen activation and cell migration

a technology of plasminogen activation and cell migration, applied in the field of new drugs, can solve the problems of limiting efficiency and the war against heart disease and stroke, and achieve the effect of preventing cell migration and reducing capillary tube formation

Inactive Publication Date: 2011-10-06
TRANSFERT PLUS
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0024]Still in accordance with the present invention, there is provided a method for treating cancer caused by cells expressing melanotransferrin (p97) at their surface, said method comprising the step of administering to a patient in need thereof exogenous soluble p97 or an antibody an antibody, or active fragment thereof, directed to said p97 expressed on the surface of said cell, said soluble p97 competing with the p97 expressed on the cell surface, activating plasminogen in solution instead of membrane-bound plasminogen, thus preventing cell migration, said antibody, or active fragment thereof binding p97 on the surface of the cell thus preventing activation of membrane-bound plasminogen, preventing cell migration, preventing cancer cells from spreading.
[0025]Further in accordance with the present invention, there is provided a method for regulating capillary tube formation, said method comprising the step administering to a patient in need thereof soluble 97, wherein said soluble p97 prevents or reduces capillary tube formation.
[0042]The term “therapeutically effective” is intended to mean an amount of a compound sufficient to substantially improve some symptom associated with a disease or a medical condition. For example, in the treatment of cancer, a compound which decreases, prevents, delays, suppresses, or arrests any symptom of the disease would be therapeutically effective. A therapeutically effective amount of a compound is not required to cure a disease but will provide a treatment for a disease such that the onset of the disease is delayed, hindered, or prevented, or the disease symptoms are ameliorated, or the term of the disease is changed or, for example, is less severe or recovery is accelerated in an individual.

Problems solved by technology

But, experts warn, the war against heart disease and stroke is not yet won.
Currently, tPA is used as a stroke therapy, however, its associated adverse effects might limit its efficiency.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound and method for regulating plasminogen activation and cell migration
  • Compound and method for regulating plasminogen activation and cell migration
  • Compound and method for regulating plasminogen activation and cell migration

Examples

Experimental program
Comparison scheme
Effect test

example i

Transcytosis of p97 through BBCEC Monolayers

[0097]Transcytosis experiments are performed at 37° C. for 2 hrs. [125I]-p97 (25 nM) is added to the upper side of the cell-covered filter in the absence or presence of RAP (650 nM) or BSA (5 μM). At the end of the experiment, radiolabelled proteins are measured in the lower chamber of each well by TCA precipitation. Results represent means±SE (n=6) (FIG. 1A). In the second part of the experiment (FIG. 1B), p97 is immobilized on a sensor chip surface (CM5) as described in the Materials and Methods section above and p97, RAP and BSA (5 μg / 100 μl) are injected over the immobilized p97.

[0098]The first evaluation was the transcytosis of p97 across an in vitro model of the BBB at 37° C. (FIG. 1A). A significant (>50%) reduction in the transport of [125I]-p97 (25 nM) from the apical (blood side) to the basolateral side (brain side) of BBCEC monolayers was observed in the presence of 640 nM RAP. Transcytosis of [1251]-p97 was unaffected by a 200-...

example ii

Pro-uPA and p97 Interaction

[0099]Biospecific Interaction Analysis between p97 and anti-p97 mAbs

[0100]Biospecific interaction analysis in real-time between p97 and various anti-p97 mAbs is performed as follows. p97 is immobilized on a sensor chip (CM5) using standard coupling procedures incorporating NHS, EDC and ethanolamine. Different mAbs directed against p97 (HybC, HybE, HybF, L235, 2C7, 9B6), diluted to 0.05 μg / μl in Ringer / Hepes, are injected into the BIAcore at a flow rate of 5 μl / min. The surface plasmon resonance response obtained for these mAbs is plotted (in relative units (RU)) as a function of time. After each injection immobilized p97 is regenerated with 0.2M glycine at pH 2 for 2 min (n=4).

[0101]To evaluate the impact of immobilization procedures on the structural integrity of p97 different mAbs directed against various conformational epitopes of p97 were injected over p97 (FIG. 2). The surface plasmon resonance (SPR) signal generated by the interaction between p97 and...

example iii

Plasminogen Activation by p97

[0108]The interaction of p97 with pro-uPA was further characterized by measuring the activation of plasminogen by pro-uPA in the presence of p97 (FIG. 5). The plasminolytic activity of 1 nM uPA was measured without (o) or with () 70 nM p97 in the presence of 30 nM plasminogen. The reaction was performed in a final volume of 200 μl as described in the Materials and Methods section above. As a control, the enzymatic activity in the presence of p97 alone was also measured (▪). When p97 is added to pro-uPA and plasminogen, the VLK-pNA hydrolysis is 4-fold higher after 180 min (FIG. 5A). Control experiments performed with p97 indicated that this protein alone does not generate plasmin when it is added to plasminogen.

[0109]The plasmin activity in the presence of various concentrations of p97 was also measured (FIG. 5B). Plasmin activity induced by pro-uPA was measured in the presence of various p97 concentrations. Since the generation of plasmin proceeds at a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.

Description

[0001]This application is a Divisional of co-pending U.S. application Ser. No. 10 / 556,145 filed on Aug. 21, 2006 and claims priority under 35 U.S.C. §120. U.S. application Ser. No. 10 / 556,145 is the national phase under 35 U.S.C. §371 of International Application No. PCT / CA2004 / 000697 filed May 7, 2004 in Canada.BACKGROUND OF THE INVENTION[0002](a) Field of the Invention[0003]The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration and treating cancer. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration and treating cancer.[0004](b) Description of the Prior Art[0005]Melanotransferrin (p97) possesses a high level of homology (37-39%) with human serum transferrin, human lactoferrin and chicken transferrin. It is a glycosylated protein that reversibly binds iron and was first found at high levels in malignant melanoma cells. Two forms of p97 have been reported, one of which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395A61K38/17A61K38/43A61P9/00A61K38/40C07K16/28
CPCA61K38/40A61K2039/505C07K2317/92C07K16/30C07K2316/96C07K16/2881A61P9/00C07K2317/76
Inventor BELIVEAU, RICHARDDEMEULE, MICHELBERTRAND, YANICKMICHAUD-LEVESQUE, JONATHANROLLAND, YANNEVEJODOIN, JULIE
Owner TRANSFERT PLUS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com